Figure 6.
Bone marrow NK cell expression of TIM3 in patients with NDMM and control subjects. (A) Proportions of NK56bright and NK56dim subsets expressing TIM3 in bone marrow of patients with NDMM and control subjects. (B) Bone marrow CD3–CD56+CD16+ NK cell TIM3 expression in patients with NDMM in those surviving <36 months and >36 months. **P ≤ .01; ns, not significant.

Bone marrow NK cell expression of TIM3 in patients with NDMM and control subjects. (A) Proportions of NK56bright and NK56dim subsets expressing TIM3 in bone marrow of patients with NDMM and control subjects. (B) Bone marrow CD3–CD56+CD16+ NK cell TIM3 expression in patients with NDMM in those surviving <36 months and >36 months. **P ≤ .01; ns, not significant.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal